The work during the initial CORT funding period established the following principles: i) periosteal MSCs respond to injury with proliferation and expansion;ii) The expanded population of MSCs secretes growth factors and responds to signals that drive bone repair;iii) COX-2/PGE2 is a key early reparative signal;iv) aging results in reduced COX-2 expression during bone repair;and 5) PTH{1-34} (PTH) compensates for the reduced healing observed in aging and COX-2[-/-] mice. The ongoing goal of Project 2 is to provide a clear and comprehensive paradigm of the cell populations and signaling mechanisms regulated by PTH during bone repair responsible for its anabolic effects.
Aims 1 and 2 use in vivo models of bone repair, while Aim 3 uses a complementary in vivo approach. Experiments in Aim 1 define periosteum as a key target for bone repair with age dependent responsiveness. The experiments will show that PTH acts specifically on periosteal MSC and stimulates three signaling pathways that are potent mediators of bone formation: Wnt/p- catenin, BMP/Smad, and lhh/Gli-2/Ptc.
Aim 2 provides genetic evidence that Wnt/Beta-catenin signaling is an essential component of the mechanism whereby PTH stimulates bone repair.
Aim 3 uses a highly innovative approach to isolate and culture periosteal stem cells. Using genetically altered mice the signals that are sequentially activated downstream of PTH are examined in isolated periosteal stem cells. Collectively, the experiments in the 3 Aims will establish that 1) PTH enhances Wnt/p-catenin and BMP/Smad signaling (stem cell proliferation/expansion, osteoblast differentiation) from periosteal/endosteal MSCs);ii) Wnt/p-catenin stimulates BMP-2 expression and BMP/Smad signaling (osteoblast differentiation/bone formation and chondrogenesis);c) BMP/Smad and Wnt/Beta-catenin signaling stimulate Ihh/Ptc signaling (bone formation). The CORT Program is based upon the unifying concept that i) expansion and differentiation of the MSC population as a critical event in musculoskeletal repair;and ii) PTH is key anabolic agent that promotes tissue specific MSC expansion and repair events. The integration of Project 2 with the other CORT Projects through an Administrative Core that enhances collaborations and access to an innovative and comprehensive Molecular and Anatomic Imaging Core will leverage the remarkable progress of the initial funding period and lead to important novel insights and therapies for orthopaedic trauma patients.

Public Health Relevance

The goal of Project 2 is to provide a clear and comprehensive paradigm of the cell populations and signaling mechanisms regulated by PTH during bone repair responsible for its anabolic effects. This provides the compelling rationale for the translation of PTH therapies to patients with bone injuries.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR054041-08
Application #
8709995
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
City
Rochester
State
NY
Country
United States
Zip Code
Yukata, Kiminori; Xie, Chao; Li, Tian-Fang et al. (2018) Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice. Bone 110:150-159
Li, Xing; Sun, Wen; Li, Jinbo et al. (2017) Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid. Sci Rep 7:41358
Schwarz, Edward M (2017) Confirmation of Sexual Dimorphisms in Metal Hypersensitivity and Joint Pain Following Total Joint Arthroplasty: Commentary on an article by Marco S. Caicedo, PhD, et al.: ""Females with Unexplained Joint Pain Following Total Joint Arthroplasty Exhibit a H J Bone Joint Surg Am 99:e41
Zhang, Longze; Wang, Tao; Chang, Martin et al. (2017) Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model. J Bone Miner Res 32:1870-1883
Feigenson, Marina; Eliseev, Roman A; Jonason, Jennifer H et al. (2017) PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell Osteogenic Differentiation by Modulating Cellular Energy Metabolism. J Cell Biochem 118:4383-4393
Wang, Wensheng; Wang, Hua; Zhou, Xichao et al. (2017) Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in Mice. J Bone Miner Res 32:939-950
Sun, Wen; Zhang, Hengwei; Wang, Hua et al. (2017) Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis. J Bone Miner Res 32:1469-1480
Le Bleu, Heather K; Kamal, Fadia A; Kelly, Meghan et al. (2017) Extraction of high-quality RNA from human articular cartilage. Anal Biochem 518:134-138
Nishitani, Kohei; Mietus, Zachary; Beck, Christopher A et al. (2017) High dose teriparatide (rPTH1-34) therapy increases callus volume and enhances radiographic healing at 8-weeks in a massive canine femoral allograft model. PLoS One 12:e0185446
Zhang, Yongchun; O'Keefe, Regis J; Jonason, Jennifer H (2017) BMP-TAK1 (MAP3K7) Induces Adipocyte Differentiation Through PPAR? Signaling. J Cell Biochem 118:204-210

Showing the most recent 10 out of 133 publications